Your session is about to expire
← Back to Search
Antihyperglycemic Agent
Empagliflozin for Cardiovascular Disease (EMPA-HEART 2 Trial)
Phase 4
Waitlist Available
Led By Subodh Verma, MD PhD
Research Sponsored by Unity Health Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
EMPA-HEART 2 Trial Summary
This trial will evaluate the effects of empagliflozin on cardiac structure, function, and circulating biomarkers in patients without diabetes but with cardiovascular risk factors.
Eligible Conditions
- Cardiovascular Disease
- Left Ventricular Hypertrophy
EMPA-HEART 2 Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Left Ventricular (LV) mass
Secondary outcome measures
Hematocrit
LV diastolic function
LV end-diastolic volume
+6 moreEMPA-HEART 2 Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: EmpagliflozinActive Control1 Intervention
Single 10 mg tablet, administered orally once daily for 6 months
Group II: PlaceboPlacebo Group1 Intervention
Single 10 mg tablet, administered orally once daily for 6 months
Find a Location
Who is running the clinical trial?
Applied Health Research CentreOTHER
22 Previous Clinical Trials
70,867 Total Patients Enrolled
Unity Health TorontoLead Sponsor
545 Previous Clinical Trials
450,303 Total Patients Enrolled
Canadian Medical and Surgical Knowledge Translation Research GroupOTHER
8 Previous Clinical Trials
770 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger